CIK 0001786205
ACLX Arcellx, Inc.
Insider trading from SEC Form 4. Last filing Sep 30, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company
Signals
Open-market buys and sells at Arcellx, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | Christopher Heery CHIEF MEDICAL OFFICER sell | $1.7M 21,034 shares | -97% | - | |
| 0Weak | Christopher Heery CHIEF MEDICAL OFFICER sell | $5,852 73 shares | -0% | - | |
| 30Weak | Christopher Heery CHIEF MEDICAL OFFICER sell | $993k 12,396 shares | -36% | - | |
| 9Weak | Christopher Heery CHIEF MEDICAL OFFICER sell | $291k 3,643 shares | -10% | - | |
| 18Weak | Kavita Patel director sell | $101k 1,500 shares | -100% | - | |
| 47Moderate | Michelle Gilson CHIEF FINANCIAL OFFICER sell | $785k 12,235 shares | -38% | - | |
| 17Weak | Kavita Patel director sell | $88k 1,500 shares | -100% | - | |
| 10Weak | Kavita Patel director sell | $96k 1,500 shares | -100% | - | |
| 9Weak | Kavita Patel director sell | $86k 1,500 shares | -100% | - | |
| 10Weak | Kavita Patel director sell | $107k 1,500 shares | -100% | - | |
| 45Moderate | Rami Elghandour SEE REMARKS sell | $2.4M 38,300 shares | -20% | - | |
| 25Weak | Kavita Patel director sell | $95k 1,500 shares | -100% | - | |
| 40Moderate | Christopher Heery CHIEF MEDICAL OFFICER sell | $648k 10,155 shares | -21% | - | |
| 10Weak | Kavita Patel director sell | $97k 1,500 shares | -100% | - | |
| 25Weak | Kavita Patel director sell | $99k 1,500 shares | -100% | - | |
| 45Moderate | Rami Elghandour SEE REMARKS sell | $2.3M 30,311 shares | -21% | - | |
| 47Moderate | Michelle Gilson CHIEF FINANCIAL OFFICER sell | $1.4M 18,009 shares | -65% | - | |
| 39Weak | Christopher Heery CHIEF MEDICAL OFFICER sell | $581k 7,783 shares | -24% | - | |
| 45Moderate | Rami Elghandour SEE REMARKS sell | $2.2M 28,633 shares | -16% | - | |
| 38Weak | Christopher Heery CHIEF MEDICAL OFFICER sell | $499k 6,362 shares | -16% | - | |
| 38Weak | Christopher Heery CHIEF MEDICAL OFFICER sell | $499k 6,362 shares | -16% | - | |
| 55Moderate | Michelle Gilson CHIEF FINANCIAL OFFICER sell | $831k 10,604 shares | -27% | - | |
| 25Weak | Kavita Patel director sell | $115k 1,500 shares | -100% | - | |
| 11Weak | Kavita Patel director sell | $138k 1,500 shares | -100% | - | |
| 26Weak | Michelle Gilson CHIEF FINANCIAL OFFICER sell | $157k 1,761 shares | -100% | - | |
| 19Weak | Kavita Patel director sell | $159k 1,500 shares | -100% | - | |
| 33Weak | Kavita Patel director sell | $6.0M 57,479 shares | -678% | - | |
| 40Moderate | Michelle Gilson CHIEF FINANCIAL OFFICER sell | $1.2M 12,354 shares | -88% | - | |
| 11Weak | Kavita Patel director sell | $135k 1,500 shares | -100% | - |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2025 | Christopher Heery CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -5,300 | $80.55 | $427k | 16,358 | Sep 30, 2025 |
| Sep 30, 2025 | Christopher Heery CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -14,204 | $81.46 | $1.2M | 2,154 | Sep 30, 2025 |
| Sep 30, 2025 | Christopher Heery CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -1,530 | $82.20 | $126k | 624 | Sep 30, 2025 |
| Sep 29, 2025 | Christopher Heery CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -73 | $80.16 | $5,852 | 21,658 | Sep 29, 2025 |
| Sep 26, 2025 | Christopher Heery CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -12,396 | $80.12 | $993k | 21,731 | Sep 26, 2025 |
| Sep 18, 2025 | Christopher Heery CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -3,343 | $80.01 | $267k | 34,427 | Sep 19, 2025 |
| Sep 19, 2025 | Christopher Heery CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -300 | $80.00 | $24k | 34,127 | Sep 19, 2025 |
| Aug 28, 2025 | Rami Elghandour SEE REMARKS | FTax withholding Common Stock | -546,938 | $70.25 | $38M | 617,919 | Aug 29, 2025 |
| Aug 12, 2025 | Ali Behbahani director | JOther Common Stock | +1,586 | $0.00 | $0 | 1,925 | Aug 14, 2025 |
| Aug 12, 2025 | Ali Behbahani director | JOther Common Stockindirect: See Note 3 | +2,621 | $0.00 | $0 | 2,706 | Aug 14, 2025 |
| Jun 10, 2025 | Kavita Patel director | MOption exercise Common Stock10b5-1 | +1,500 | $6.66 | $9,990 | 1,500 | Jun 11, 2025 |
| Jun 10, 2025 | Kavita Patel director | SOpen-market sale Common Stock10b5-1 | -1,500 | $67.36 | $101k | 0 | Jun 11, 2025 |
| Jun 10, 2025 | Kavita Patel director | MOption exercise Stock Option (right to buy)derivative10b5-1 | -1,500 | $0.00 | $0 | 27,077 | Jun 11, 2025 |
| May 29, 2025 | David Charles Lubner director | AGrant or award Stock Option (right to buy)derivative | +9,174 | $0.00 | $0 | 9,174 | May 30, 2025 |
| May 29, 2025 | Jill Carroll director | AGrant or award Stock Option (right to buy)derivative | +9,174 | $0.00 | $0 | 9,174 | May 30, 2025 |
| May 29, 2025 | Kristin Myers director | AGrant or award Stock Option (right to buy)derivative | +1,784 | $0.00 | $0 | 1,784 | May 30, 2025 |
| May 29, 2025 | Kavita Patel director | AGrant or award Stock Option (right to buy)derivative | +9,174 | $0.00 | $0 | 9,174 | May 30, 2025 |
| May 29, 2025 | Andrew H Galligan director | AGrant or award Stock Option (right to buy)derivative | +1,784 | $0.00 | $0 | 1,784 | May 30, 2025 |
| May 29, 2025 | Olivia C Ware director | AGrant or award Stock Option (right to buy)derivative | +9,174 | $0.00 | $0 | 9,174 | May 30, 2025 |
| May 29, 2025 | Ali Behbahani director | AGrant or award Stock Option (right to buy)derivative | +9,174 | $0.00 | $0 | 9,174 | May 30, 2025 |
| May 23, 2025 | Michelle Gilson CHIEF FINANCIAL OFFICER | MOption exercise Common Stock | +22,429 | $0.00 | $0 | 32,011 | May 28, 2025 |
| May 27, 2025 | Michelle Gilson CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock | -3,786 | $63.62 | $241k | 28,225 | May 28, 2025 |
| May 27, 2025 | Michelle Gilson CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock | -8,449 | $64.38 | $544k | 19,776 | May 28, 2025 |
| May 23, 2025 | Michelle Gilson CHIEF FINANCIAL OFFICER | MOption exercise Restricted Stock Unitsderivative | -22,429 | $0.00 | $0 | 0 | May 28, 2025 |
| May 20, 2025 | Kavita Patel director | MOption exercise Common Stock10b5-1 | +1,500 | $6.66 | $9,990 | 1,500 | May 20, 2025 |
| May 20, 2025 | Kavita Patel director | SOpen-market sale Common Stock10b5-1 | -1,500 | $58.43 | $88k | 0 | May 20, 2025 |
| May 20, 2025 | Kavita Patel director | MOption exercise Stock Option (right to buy)derivative10b5-1 | -1,500 | $0.00 | $0 | 28,577 | May 20, 2025 |
| Apr 29, 2025 | Kavita Patel director | MOption exercise Common Stock10b5-1 | +1,500 | $6.66 | $9,990 | 1,500 | Apr 29, 2025 |
| Apr 29, 2025 | Kavita Patel director | SOpen-market sale Common Stock10b5-1 | -1,500 | $64.20 | $96k | 0 | Apr 29, 2025 |
| Apr 29, 2025 | Kavita Patel director | MOption exercise Stock Option (right to buy)derivative10b5-1 | -1,500 | $0.00 | $0 | 30,077 | Apr 29, 2025 |
| Apr 8, 2025 | Kavita Patel director | MOption exercise Common Stock10b5-1 | +1,500 | $6.66 | $9,990 | 1,500 | Apr 8, 2025 |
| Apr 8, 2025 | Kavita Patel director | SOpen-market sale Common Stock10b5-1 | -1,500 | $57.50 | $86k | 0 | Apr 8, 2025 |
| Apr 8, 2025 | Kavita Patel director | MOption exercise Stock Option (right to buy)derivative10b5-1 | -1,500 | $0.00 | $0 | 31,577 | Apr 8, 2025 |
| Mar 18, 2025 | Andrew H Galligan director | AGrant or award Stock Option (right to buy)derivative | +16,829 | $0.00 | $0 | 16,829 | Mar 20, 2025 |
| Mar 18, 2025 | Kristin Myers director | AGrant or award Stock Option (right to buy)derivative | +16,829 | $0.00 | $0 | 16,829 | Mar 20, 2025 |
| Mar 18, 2025 | Kavita Patel director | MOption exercise Common Stock10b5-1 | +1,500 | $6.66 | $9,990 | 1,500 | Mar 18, 2025 |
| Mar 18, 2025 | Kavita Patel director | SOpen-market sale Common Stock10b5-1 | -1,500 | $71.64 | $107k | 0 | Mar 18, 2025 |
| Mar 18, 2025 | Kavita Patel director | MOption exercise Stock Option (right to buy)derivative10b5-1 | -1,500 | $0.00 | $0 | 33,077 | Mar 18, 2025 |
| Feb 27, 2025 | Rami Elghandour SEE REMARKS | AGrant or award Common Stock | +668,416 | $0.00 | $0 | 817,602 | Feb 27, 2025 |
| Feb 27, 2025 | Rami Elghandour SEE REMARKS | AGrant or award Common Stock | +347,255 | $0.00 | $0 | 1,164,857 | Feb 27, 2025 |
| Feb 7, 2025 | Rami Elghandour SEE REMARKS | MOption exercise Common Stock | +70,211 | $0.00 | $0 | 187,486 | Feb 26, 2025 |
| Feb 26, 2025 | Rami Elghandour SEE REMARKS | SOpen-market sale Common Stock | -6,334 | $61.14 | $387k | 181,152 | Feb 26, 2025 |
| Feb 26, 2025 | Rami Elghandour SEE REMARKS | SOpen-market sale Common Stock | -21,077 | $61.95 | $1.3M | 160,075 | Feb 26, 2025 |
| Feb 26, 2025 | Rami Elghandour SEE REMARKS | SOpen-market sale Common Stock | -10,889 | $62.69 | $683k | 149,186 | Feb 26, 2025 |
| Feb 7, 2025 | Rami Elghandour SEE REMARKS | MOption exercise Restricted Stock Unitderivative | -70,211 | $0.00 | $0 | 0 | Feb 26, 2025 |
| Feb 25, 2025 | Kavita Patel director | MOption exercise Common Stock10b5-1 | +1,500 | $6.66 | $9,990 | 1,500 | Feb 25, 2025 |
| Feb 25, 2025 | Kavita Patel director | SOpen-market sale Common Stock10b5-1 | -1,500 | $63.16 | $95k | 0 | Feb 25, 2025 |
| Feb 25, 2025 | Kavita Patel director | MOption exercise Stock Option (right to buy)derivative10b5-1 | -1,500 | $0.00 | $0 | 34,577 | Feb 25, 2025 |
| Feb 7, 2025 | Christopher Heery CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +22,556 | $0.00 | $0 | 47,641 | Feb 24, 2025 |
| Feb 24, 2025 | Christopher Heery CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock | -4,370 | $63.14 | $276k | 43,271 | Feb 24, 2025 |
| Feb 24, 2025 | Christopher Heery CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock | -5,577 | $64.26 | $358k | 37,694 | Feb 24, 2025 |
| Feb 24, 2025 | Christopher Heery CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock | -208 | $64.88 | $13k | 37,486 | Feb 24, 2025 |
| Feb 7, 2025 | Christopher Heery CHIEF MEDICAL OFFICER | MOption exercise Restricted Stock Unitderivative | -22,556 | $0.00 | $0 | 0 | Feb 24, 2025 |
| Feb 7, 2025 | Rami Elghandour SEE REMARKS | MOption exercise Common Stock | +70,211 | $0.00 | $0 | 187,486 | Feb 11, 2025 |
| Feb 7, 2025 | Christopher Heery CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +22,556 | $0.00 | $0 | 47,641 | Feb 11, 2025 |
| Feb 7, 2025 | Rami Elghandour SEE REMARKS | MOption exercise Restricted Stock Unitderivative | -70,211 | $0.00 | $0 | 0 | Feb 11, 2025 |
| Feb 7, 2025 | Christopher Heery CHIEF MEDICAL OFFICER | MOption exercise Restricted Stock Unitderivative | -22,556 | $0.00 | $0 | 0 | Feb 11, 2025 |
| Feb 4, 2025 | Kavita Patel director | MOption exercise Common Stock10b5-1 | +1,500 | $6.66 | $9,990 | 1,500 | Feb 4, 2025 |
| Feb 4, 2025 | Kavita Patel director | SOpen-market sale Common Stock10b5-1 | -1,500 | $64.57 | $97k | 0 | Feb 4, 2025 |
| Feb 4, 2025 | Kavita Patel director | MOption exercise Stock Option (right to buy)derivative10b5-1 | -1,500 | $0.00 | $0 | 36,077 | Feb 4, 2025 |
| Jan 14, 2025 | Kavita Patel director | MOption exercise Common Stock10b5-1 | +1,500 | $6.66 | $9,990 | 1,500 | Jan 14, 2025 |
| Jan 14, 2025 | Kavita Patel director | SOpen-market sale Common Stock10b5-1 | -800 | $64.95 | $52k | 700 | Jan 14, 2025 |
| Jan 14, 2025 | Kavita Patel director | SOpen-market sale Common Stock10b5-1 | -400 | $66.62 | $27k | 300 | Jan 14, 2025 |
| Jan 14, 2025 | Kavita Patel director | SOpen-market sale Common Stock10b5-1 | -300 | $67.32 | $20k | 0 | Jan 14, 2025 |
| Jan 14, 2025 | Kavita Patel director | MOption exercise Stock Option (right to buy)derivative10b5-1 | -1,500 | $0.00 | $0 | 37,577 | Jan 14, 2025 |
| Jan 3, 2025 | Christopher Heery CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +16,519 | $0.00 | $0 | 38,818 | Jan 10, 2025 |
| Jan 3, 2025 | Rami Elghandour SEE REMARKS | MOption exercise Common Stock | +53,097 | $0.00 | $0 | 177,809 | Jan 10, 2025 |
| Jan 3, 2025 | Michelle Gilson CHIEF FINANCIAL OFFICER | MOption exercise Common Stock10b5-1 | +15,339 | $0.00 | $0 | 38,834 | Jan 10, 2025 |
| Jan 7, 2025 | Rami Elghandour SEE REMARKS | SOpen-market sale Common Stock | -16,474 | $75.53 | $1.2M | 131,112 | Jan 10, 2025 |
| Jan 7, 2025 | Michelle Gilson CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -3,128 | $74.43 | $233k | 24,463 | Jan 10, 2025 |
| Jan 7, 2025 | Christopher Heery CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock | -4,230 | $75.53 | $319k | 28,638 | Jan 10, 2025 |
| Jan 8, 2025 | Rami Elghandour SEE REMARKS | SOpen-market sale Common Stock | -13,837 | $73.69 | $1.0M | 117,275 | Jan 10, 2025 |
| Jan 8, 2025 | Christopher Heery CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock | -3,553 | $73.69 | $262k | 25,085 | Jan 10, 2025 |
| Jan 7, 2025 | Michelle Gilson CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -1,546 | $75.23 | $116k | 22,917 | Jan 10, 2025 |
| Jan 7, 2025 | Michelle Gilson CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -2,251 | $76.64 | $173k | 20,666 | Jan 10, 2025 |
| Jan 3, 2025 | Rami Elghandour SEE REMARKS | MOption exercise Restricted Stock Unitderivative | -53,097 | $0.00 | $0 | 53,098 | Jan 10, 2025 |
| Jan 3, 2025 | Christopher Heery CHIEF MEDICAL OFFICER | MOption exercise Restricted Stock Unitderivative | -16,519 | $0.00 | $0 | 16,520 | Jan 10, 2025 |
| Jan 7, 2025 | Michelle Gilson CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -2,327 | $77.06 | $179k | 18,339 | Jan 10, 2025 |
| Jan 7, 2025 | Michelle Gilson CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -4,760 | $75.53 | $360k | 13,579 | Jan 10, 2025 |
| Jan 8, 2025 | Michelle Gilson CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -3,997 | $73.69 | $295k | 9,582 | Jan 10, 2025 |
| Jan 3, 2025 | Michelle Gilson CHIEF FINANCIAL OFFICER | MOption exercise Restricted Stock Unitderivative10b5-1 | -15,339 | $0.00 | $0 | 15,340 | Jan 10, 2025 |
| Jan 2, 2025 | Michelle Gilson CHIEF FINANCIAL OFFICER | MOption exercise Common Stock | +20,495 | $0.00 | $0 | 23,495 | Jan 6, 2025 |
| Jan 2, 2025 | Christopher Heery CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +13,021 | $0.00 | $0 | 22,299 | Jan 6, 2025 |
| Jan 2, 2025 | Christopher Heery CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +13,021 | $0.00 | $0 | 22,299 | Jan 6, 2025 |
| Jan 2, 2025 | Rami Elghandour SEE REMARKS | MOption exercise Common Stock | +55,459 | $0.00 | $0 | 124,712 | Jan 6, 2025 |
| Jan 3, 2025 | Rami Elghandour SEE REMARKS | MOption exercise Common Stock | +53,097 | $0.00 | $0 | 177,809 | Jan 6, 2025 |
| Jan 3, 2025 | Christopher Heery CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +16,519 | $0.00 | $0 | 38,818 | Jan 6, 2025 |
| Jan 3, 2025 | Christopher Heery CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +16,519 | $0.00 | $0 | 38,818 | Jan 6, 2025 |
| Jan 3, 2025 | Michelle Gilson CHIEF FINANCIAL OFFICER | MOption exercise Common Stock | +15,339 | $0.00 | $0 | 38,834 | Jan 6, 2025 |
| Jan 3, 2025 | Rami Elghandour SEE REMARKS | SOpen-market sale Common Stock | -14,857 | $79.55 | $1.2M | 162,952 | Jan 6, 2025 |
| Jan 3, 2025 | Christopher Heery CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock | -3,301 | $79.55 | $263k | 35,517 | Jan 6, 2025 |
| Jan 3, 2025 | Christopher Heery CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock | -3,301 | $79.55 | $263k | 35,517 | Jan 6, 2025 |
| Jan 3, 2025 | Michelle Gilson CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock | -5,502 | $79.55 | $438k | 33,332 | Jan 6, 2025 |
| Jan 6, 2025 | Rami Elghandour SEE REMARKS | SOpen-market sale Common Stock | -13,776 | $77.17 | $1.1M | 149,176 | Jan 6, 2025 |
| Jan 6, 2025 | Christopher Heery CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock | -3,061 | $77.17 | $236k | 32,456 | Jan 6, 2025 |
| Jan 6, 2025 | Christopher Heery CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock | -3,061 | $77.17 | $236k | 32,456 | Jan 6, 2025 |
| Jan 6, 2025 | Michelle Gilson CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock | -5,102 | $77.17 | $394k | 28,230 | Jan 6, 2025 |
| Jan 2, 2025 | Christopher Heery CHIEF MEDICAL OFFICER | MOption exercise Restricted Stock Unitderivative | -13,021 | $0.00 | $0 | 26,042 | Jan 6, 2025 |
| Jan 2, 2025 | Christopher Heery CHIEF MEDICAL OFFICER | MOption exercise Restricted Stock Unitderivative | -13,021 | $0.00 | $0 | 26,042 | Jan 6, 2025 |
| Jan 2, 2025 | Rami Elghandour SEE REMARKS | MOption exercise Restricted Stock Unitderivative | -55,459 | $0.00 | $0 | 110,918 | Jan 6, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Ali Behbahaniowner, director
- Jill Carrolldirector
- Rami ElghandourSEE REMARKS
- Andrew H Galligandirector
- Michelle GilsonCHIEF FINANCIAL OFFICER
- Christopher HeeryCHIEF MEDICAL OFFICER
- David Charles Lubnerdirector
- Kristin Myersdirector
- Kavita Pateldirector
- Olivia C Waredirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.